Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity
作者:Hao Chen、Xiuhui Chen、Ping Sun、Dan Wu、Hu Yue、Jintao Pan、Xinxuan Li、Cheng Zhang、Xinyi Wu、Lei Hua、Wenhui Hu、Zhongjin Yang
DOI:10.1016/j.bmcl.2021.128160
日期:2021.8
Inhibiting NLRP3 inflammasome activation is a prospective therapeutic strategy for uncontrolled inflammatory diseases. It is the first time that dronedarone, a multiply ion channel blocker, was identified as a NLRP3-inflammasome inhibitor with an IC50 value of 6.84 μM against IL-1β release. A series of novel 5-amide benzofuran derivatives were designed and synthesized as NLRP3-inflammasome inhibitors
抑制 NLRP3 炎症小体激活是治疗不受控制的炎症疾病的前瞻性治疗策略。这是第一次将多离子通道阻滞剂决奈达隆鉴定为 NLRP3 炎症小体抑制剂,其抑制IL-1 β释放的 IC 50值为 6.84 μM 。设计并合成了一系列新型 5-酰胺苯并呋喃衍生物作为 NLRP3 炎症小体抑制剂。化合物 8c对 IL-1 β释放的活性略有增加(IC 50 = 3.85 μM)。值得注意的是,用 8c 处理可以显着抑制 NLRP3 介导的 IL-1 β在脓毒症小鼠模型中释放和改善腹膜炎症。总的来说,8c 是一种有前途的先导化合物,可作为具有抗炎作用的 NLRP3 抑制剂进行进一步的化学开发。